Neoadjuvant Plus Adjuvant Dabrafenib and Trametinib Versus Standard of Care in Patients With High-Risk, Surgically Resectable Melanoma: A Single-Centre, Open-Label, Randomised, Phase 2 Trial. The Lancet - Amaria, RN; Prieto, PA; Tetzlaff, MT (Oncology, 2018)
et al.